Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Immunogenicity of pHIS-HIV-AE DNA Prime and rFPV-HIV-AE Boost HIV Vaccine Strategy
NCT00333424Phase 2Terminated
- Sponsor
- The Kirby Institute
- Start
- Aug 2007
- Primary completion
- Jul 2008
- Modality
- Prophylactic Vaccines, Viral Vectors, DNA Vaccines
- Countries
- 1
01
Overview
A Phase 2 trial of pHIS-HIV-AE, rFPV-HIV-AE in human immunodeficiency virus infection (HIV), sponsored by The Kirby Institute. Started Aug 2007; status: terminated.
02
Drugs
pHIS-HIV-AErFPV-HIV-AE
03
Conditions
human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on NCT00333424.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00333424.